3 years ago

Thrombocytopenia with tedizolid and linezolid.

Erica Yookyung Lee, Aisling Caffrey
Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved 06/2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration Adverse Event Reporting System (07/2014-12/2016), we observed a significantly increased risk of thrombocytopenia of similar magnitude with both antibiotics: linezolid reporting odds ratio [ROR] 37.9 (95% confidence interval [CI] 20.78-69.17); tedizolid ROR 34.0 (95% CI 4.67- 247.30).

Publisher URL: http://doi.org/10.1128/AAC.01453-17

DOI: 10.1128/AAC.01453-17

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.